Paricalcitol alleviates lipopolysaccharide-induced depressive-like behavior by suppressing hypothalamic microglia...

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Depression is common in chronic inflammatory diseases, linked to neuroinflammation and microglia activation.
• Paricalcitol (Pari), a vitamin D2 analogue, shows anti-inflammatory effects in other conditions.
• The role of neuroinflammation in depression pathogenesis is increasingly recognized.

Purpose of the Study:

• To investigate the anti-depressant effects of paricalcitol in an inflammation-induced depression mouse model.
• To examine paricalcitol's impact on neuroinflammation, microglia activity, and the renin-angiotensin system.
• To assess paricalcitol's potential therapeutic value for depression associated with systemic inflammation.

Main Methods:

• Mice were pretreated with paricalcitol before lipopolysaccharide (LPS) injection to induce depression-like behaviors.
• Behavioral tests included body weight, sucrose preference, forced swimming (FST), and tail suspension (TST).
• Pro-inflammatory cytokine IL-1β levels and hypothalamic microglia activity were analyzed.

Main Results:

• Paricalcitol significantly alleviated LPS-induced depressive-like behaviors.
• Key indicators of improvement included increased sucrose preference and reduced immobility in FST and TST.
• Paricalcitol modulated microglia-mediated neuroinflammation and renin-angiotensin system activity.

Conclusions:

• Paricalcitol demonstrates potential as an anti-depressant agent for inflammation-induced depression.
• The mechanism involves regulating microglia-mediated neuroinflammation and the renin-angiotensin system.
• This finding is particularly relevant for patients with chronic inflammation and hypertension.